Related Experiment Videos
Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells
Tokuhiro Chano1, Shiro Ikegawa, Keiichi Kontani
1Department of Basic Science for Health and Nursing, Shiga University of Medical Science, Tsukinowa-cho, Otsu, Shiga 520-2192, Japan. chano@belle.shiga-med.ac.jp
Abstract:
Multidrug resistance to anti-cancer agents (MDR) is a major barrier to successful cancer treatment. Current knowledge about genes that contribute to MDR is limited, however, and its mechanisms remain unclear. To identify genes involved in MDR, we performed differential display analysis and isolated a novel human gene, RB1CC1 (RBI-inducible Coiled-Coil 1). The 6.6-kb RB1CC1 cDNA encodes a putative 1594-amino-acid protein that contains a nuclear localization signal, a leucine zipper motif and a coiled-coil structure. Western blot analysis and immunocytochemical staining with anti-RB1CC1 antibody showed that endogenously expressed RB1CC1 protein localized to the nucleus. In MDR variants of human osteosarcoma cells, RB1CC1 expression increased in response to doxorubicin-induced cytotoxic stress and remained elevated for the duration of drug treatment. RB1CC1 expression levels correlated closely with those of RB1 (retinoblastoma 1) in cancer cell lines as well as in various normal human tissues. Moreover, introduction of wild-type RB1CC1 significantly induced RB1 expression in human leukemic cells. These data suggest that RB1CC1 may be a key regulator of RB1 gene expression.
Insights
Researchers identified a new gene, RB1CC1, involved in multidrug resistance (MDR) in cancer. RB1CC1 expression increases under drug stress and regulates the RB1 gene, offering potential new therapeutic targets for overcoming cancer drug resistance.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Multidrug resistance (MDR) to anti-cancer drugs is a significant obstacle in effective cancer therapy.
- The genetic factors and mechanisms underlying MDR are not fully understood.
- Identifying novel genes involved in MDR is crucial for developing new treatment strategies.
Purpose of the Study:
- To identify novel genes contributing to multidrug resistance (MDR) in cancer.
- To characterize the function and regulation of the newly identified gene, RB1CC1.
- To investigate the relationship between RB1CC1 and the RB1 gene in cancer cells.
Main Methods:
- Differential display analysis was employed to identify genes associated with MDR.
- RB1CC1 cDNA was cloned and its protein product characterized.
- Western blot and immunocytochemical staining were used to determine RB1CC1 protein localization and expression levels.
- RB1CC1 expression was analyzed in MDR cancer cells under doxorubicin treatment.
- Correlation studies were performed between RB1CC1 and RB1 expression in various cell lines and human tissues.
Main Results:
- A novel human gene, RB1CC1, was identified as being involved in MDR.
- RB1CC1 encodes a nuclear protein with a coiled-coil structure.
- RB1CC1 expression was upregulated in doxorubicin-resistant osteosarcoma cells under cytotoxic stress.
- RB1CC1 expression levels showed a strong correlation with RB1 expression across different cancer cell lines and normal human tissues.
- Introduction of RB1CC1 into human leukemic cells led to a significant induction of RB1 expression.
Conclusions:
- RB1CC1 is a novel gene implicated in multidrug resistance (MDR).
- RB1CC1 protein localizes to the nucleus and its expression is induced by anti-cancer drug stress.
- RB1CC1 appears to play a regulatory role in RB1 gene expression, suggesting a potential mechanism for overcoming MDR.